Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline landscape.

Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.




Introduction 5
Global Markets Direct Report Coverage 5
Burkholderia pseudomallei Infections (Melioidosis) - Overview 6
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development 20
Bavarian Nordic A/S 20
Emergent BioSolutions Inc 20
Grifols SA 21
MerLion Pharmaceuticals Pte Ltd 21
Soligenix Inc 22
Syntiron LLC 22
Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles 24
ARD-3100 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
ARD-3150 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Burkholderia pseudomallei vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Burkholderia vaccine - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
EV-035 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
finafloxacin - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
GC-072 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
melioidosis vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
SGX-943 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules for Infectious Diseases - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects 46
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products 47
Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones 48
Featured News & Press Releases 48
Jun 28, 2017: MerLion and Dstl Awarded DTRA Grant to Explore the Use of Finafloxacin against Biological Threat Agents 48
May 31, 2016: FDA Grants Soligenix Fast Track Designation for SGX943 for the Treatment of Melioidosis 48
Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC 49
Aug 14, 2014: US DTRA to fund preclinical work on Evolvas antibiotic GC-072 49
Feb 21, 2014: Bavarian Nordics MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development 50
Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List Of Tables


Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Products under Development by Companies, H2 2017 10
Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Stage and Target, H2 2017 13
Number of Products by Stage and Mechanism of Action, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bavarian Nordic A/S, H2 2017 20
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Emergent BioSolutions Inc, H2 2017 21
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Grifols SA, H2 2017 21
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017 22
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, H2 2017 22
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Syntiron LLC, H2 2017 23
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H2 2017 46
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H2 2017 47

List Of Figures


Number of Products by Targets, H2 2017 12
Number of Products by Stage and Targets, H2 2017 12
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 18

2018 Global Drugs for Burkholderia Infections Industry Report - History, Present and Future

The global market size of Drugs for Burkholderia Infections is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by

USD 4000 View Report

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2018

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2018, provides an overview

USD 2000 View Report

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2018

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2018, provides an overview

USD 2000 View Report

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017, provides an overview

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available